Table 3 Comparison of clinical characteristics in cases whose ICW_BIA decreased or increased after six hours of add-on tolvaptan

N

17 (57%)

13 (43%)

–

Age, years

69 [46–87]

65 [51–80]

0.325

Sex, M/F

9/8

8/5

0.721

 Child-Pugh-Turcotte B/C

11/6

4/9

0.139

 MELD score

13 [8–23]

16 [8–29]

0.075

 MELDNa score

17 [8–30]

21 [13–32]

0.047*

 MAP, mmHg

81 [65–104]

82 [76–106]

0.818

 Furosemide, mg/day

25 [0–160]

20 [0–80]

0.589

Spironolactone, mg/day

25 [0–100]

50 [0–75]

0.825

 Total bilirubin, mg/dL

1.5 [0.3–12.6]

3.5 [1.1–8.3]

0.040*

 PT-INR

1.20 [0.96–1.75]

1.33 [1.03–2.42]

0.476

 Serum sodium, mmol/L

135.6 [123.1–142.8]

133 [122.3–40.0]

0.368

 Albumin, g/dL

2.6 [1.6–3.1]

2.3 [1.8–3.9]

0.867

 BUN, mg/dL

18.2 [5.9–47.1]

25.3 [11.9–46.3]

0.054

 Serum creatinine, mg/dL

0.99 [0.48–2.49]

1.01 [0.48–2.13]

0.786

 ALT, IU/L

20 [7–75]

39 [11–69]

0.019*

 GGTP, IU/L

64 [14–264]

95 [11–359]

0.315

 AVP, pg/mL

1.4 [0.8–5.1]

2.3 [1.2–6.3]

0.076

 Aldosterone, pg/mL

116 [18–407]

333 [107–1200]

0.012*

 Serum osmolality, mOsm/kg. H₂O

287 [250–295]

280 [273–293]

0.659

 Urine osmolality, mOsm/kg. H₂O

441 [272–691]

485 [59–838]

0.267